SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2

Young-Suk Lim; Chun-Yen Lin; Jeong Heo; Ho Bae; Wan-Long Chuang; Tak Yin; Owen Tsang; Claire Fournier; Aric Josun Hui; Huy Trinh; Carol Yee Kwan Chan; Susanna K. Tan; Yang Zhao; John F. Flaherty; Vithika Suri; Anuj Gaggar; Dianna M. Brainard; Stephen Ryder; Harry La Janssen

doi:10.1136/gutjnl-2021-IDDF.81

SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2

Young-Suk Lim
, Chun-Yen Lin
, Jeong Heo
, Ho Bae
, Wan-Long Chuang
, Tak Yin
, Owen Tsang
, Claire Fournier
, Aric Josun Hui
, Huy Trinh
, Carol Yee Kwan Chan
, Susanna K. Tan
, Yang Zhao
, John F. Flaherty
, Vithika Suri
, Anuj Gaggar
, Dianna M. Brainard
, Stephen Ryder
, Harry La Janssen

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

Original language	American English
Journal	Gut
Volume	70
DOIs	https://doi.org/10.1136/gutjnl-2021-IDDF.81
State	Published - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1136/gutjnl-2021-IDDF.81

Cite this

Lim, Y.-S., Lin, C.-Y., Heo, J., Bae, H., Chuang, W.-L., Yin, T., Tsang, O., Fournier, C., Hui, A. J., Trinh, H., Chan, C. Y. K., Tan, S. K., Zhao, Y., Flaherty, J. F., Suri, V., Gaggar, A., Brainard, D. M., Ryder, S., & La Janssen, H. (2021). SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2. Gut, 70. https://doi.org/10.1136/gutjnl-2021-IDDF.81

@article{50771991c1204ef090dd17b3f8622f15,

title = "SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2",

author = "Young-Suk Lim and Chun-Yen Lin and Jeong Heo and Ho Bae and Wan-Long Chuang and Tak Yin and Owen Tsang and Claire Fournier and Hui, \{Aric Josun\} and Huy Trinh and Chan, \{Carol Yee Kwan\} and Tan, \{Susanna K.\} and Yang Zhao and Flaherty, \{John F.\} and Vithika Suri and Anuj Gaggar and Brainard, \{Dianna M.\} and Stephen Ryder and \{La Janssen\}, Harry",

year = "2021",

doi = "10.1136/gutjnl-2021-IDDF.81",

language = "American English",

volume = "70",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

}

Lim, Y-S, Lin, C-Y, Heo, J, Bae, H, Chuang, W-L, Yin, T, Tsang, O, Fournier, C, Hui, AJ, Trinh, H, Chan, CYK, Tan, SK, Zhao, Y, Flaherty, JF, Suri, V, Gaggar, A, Brainard, DM, Ryder, S & La Janssen, H 2021, 'SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2', Gut, vol. 70. https://doi.org/10.1136/gutjnl-2021-IDDF.81

SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2. / Lim, Young-Suk; Lin, Chun-Yen; Heo, Jeong et al.
In: Gut, Vol. 70, 2021.

Research output: Contribution to journal › Journal Article › peer-review

TY - JOUR

T1 - SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2

AU - Lim, Young-Suk

AU - Lin, Chun-Yen

AU - Heo, Jeong

AU - Bae, Ho

AU - Chuang, Wan-Long

AU - Yin, Tak

AU - Tsang, Owen

AU - Fournier, Claire

AU - Hui, Aric Josun

AU - Trinh, Huy

AU - Chan, Carol Yee Kwan

AU - Tan, Susanna K.

AU - Zhao, Yang

AU - Flaherty, John F.

AU - Suri, Vithika

AU - Gaggar, Anuj

AU - Brainard, Dianna M.

AU - Ryder, Stephen

AU - La Janssen, Harry

PY - 2021

Y1 - 2021

U2 - 10.1136/gutjnl-2021-IDDF.81

DO - 10.1136/gutjnl-2021-IDDF.81

M3 - Journal Article

SN - 0017-5749

VL - 70

JO - Gut

JF - Gut

ER -